Am J Psychiatry 160:1909-1918, November 2003
© 2003 American Psychiatric Association
Variables That Affect the Clinical Use and Abuse of Methylphenidate in the Treatment of ADHD
Nora D. Volkow, M.D., and
James M. Swanson, Ph.D.
OBJECTIVE: Methylphenidate, the most common treatment for attention deficit hyperactivity disorder (ADHD), increases extracellular dopamine in the brain, which is associated with its reinforcing as well as its therapeutic effects. The authors evaluated variables that distinguish these two properties. METHOD: The brain imaging and clinical literatures were analyzed to identify variables that contribute to the abuse liability as well as to the clinical efficacy of methylphenidate. RESULTS: Four variables were identified. 1) Dose—there is a threshold for methylphenidate-induced dopamine increases to be perceived as reinforcing and to produce therapeutic effects. 2) Pharmacokinetics—the reinforcing effects of methylphenidate are associated with rapid changes in serum concentrations and presumably fast dopamine increases (as achieved with intravenous injection or insufflation), whereas the therapeutic effects are associated with slowly ascending serum concentrations and presumably smoothly rising dopamine levels (as achieved with oral administration). 3) Individual differences—sensitivity to methylphenidate varies across individuals and sets a threshold for blood and brain levels required for reinforcing effects (drug liking) and for therapeutic effects (symptom reduction). 4) Context—the effects of methylphenidate are modulated by different settings in abuse (rituals of self-administration and powerful conditioning) and in clinical use (external demands of low activity and focused attention). CONCLUSIONS: Reinforcing effects occur when methylphenidate elicits large and fast dopamine increases that mimic those of phasic dopamine cell firing, whereas therapeutic effects occur when methylphenidate elicits slow, steady-state dopamine increases that mimic those of tonic firing. Thus, the characteristics of clinical use (low doses administered orally and titrated for therapeutic effects) constrain methylphenidate’s abuse.
This article has been cited by other articles:
|
|
|
|
 
S. J. Schubert, S. Hansen, K. R. Dyer, and M. Rapley
`ADHD patient' or `illicit drug user'? Managing medico-moral membership categories in drug dependence services
Discourse Society,
July 1, 2009;
20(4):
499 - 516.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. M. Goos, J. Crosbie, S. Payne, and R. Schachar
Validation and Extension of the Endophenotype Model in ADHD Patterns of Inheritance in a Family Study of Inhibitory Control
Am J Psychiatry,
June 1, 2009;
166(6):
711 - 717.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Jasinski and S Krishnan
Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse
J Psychopharmacol,
June 1, 2009;
23(4):
419 - 427.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. H. Kollins
ADHD, Substance Use Disorders, and Psychostimulant Treatment: Current Literature and Treatment Guidelines
J Atten Disord,
September 1, 2008;
12(2):
115 - 125.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. D. Volkow and J. M. Swanson
Does Childhood Treatment of ADHD With Stimulant Medication Affect Substance Abuse in Adulthood?
Am J Psychiatry,
May 1, 2008;
165(5):
553 - 555.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Gunzler, C. Koudelka, N. E. Carlson, M. Pavel, and J. G. Nutt
Effect of Low Concentrations of Apomorphine on Parkinsonism in a Randomized, Placebo-Controlled, Crossover Study
Arch Neurol,
February 1, 2008;
65(2):
193 - 198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. DuPont, R. H. Bucher, B. B. Wilford, and J. J. Coleman
School-Based Administration of ADHD Drugs Decline, Along With Diversion, Theft, and Misuse
The Journal of School Nursing,
December 1, 2007;
23(6):
349 - 352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. A. Parasrampuria, K. A. Schoedel, R. Schuller, J. Gu, P. Ciccone, S. A. Silber, and E. M. Sellers
Assessment of Pharmacokinetics and Pharmacodynamic Effects Related to Abuse Potential of a Unique Oral Osmotic-Controlled Extended-Release Methylphenidate Formulation in Humans
J. Clin. Pharmacol.,
December 1, 2007;
47(12):
1476 - 1488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Volkow, G.-J. Wang, J. Newcorn, F. Telang, M. V. Solanto, J. S. Fowler, J. Logan, Y. Ma, K. Schulz, K. Pradhan, et al.
Depressed Dopamine Activity in Caudate and Preliminary Evidence of Limbic Involvement in Adults With Attention-Deficit/Hyperactivity Disorder
Arch Gen Psychiatry,
August 1, 2007;
64(8):
932 - 940.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Advokat
Literature Review: Update on Amphetamine Neurotoxicity and Its Relevance to the Treatment of ADHD
J Atten Disord,
July 1, 2007;
11(1):
8 - 16.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. D. VOLKOW
Stimulant Medications: How to Minimize Their Reinforcing Effects?
Am J Psychiatry,
March 1, 2006;
163(3):
359 - 361.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Moore, J. Biederman, J. Wozniak, E. Mick, M. Aleardi, M. Wardrop, M. Dougherty, T. Harpold, P. Hammerness, E. Randall, et al.
Differences in Brain Chemistry in Children and Adolescents With Attention Deficit Hyperactivity Disorder With and Without Comorbid Bipolar Disorder: A Proton Magnetic Resonance Spectroscopy Study
Am J Psychiatry,
February 1, 2006;
163(2):
316 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Thapar, M. O'Donovan, and M. J Owen
The genetics of attention deficit hyperactivity disorder
Hum. Mol. Genet.,
October 15, 2005;
14(suppl_2):
R275 - R282.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Coghill
Attention-deficit hyperactivity disorder: should we believe the mass media or peer-reviewed literature?
Psychiatr. Bull.,
August 1, 2005;
29(8):
288 - 291.
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2003
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
